Strategic Situation 03
Parallel International Registration: Access Consortium or Project Orbis Strategy
Strategic Situation 03
01
04
International Strategy · Access Consortium · Project Orbis · Parallel Submissions · US Biopharma
02
04
Situation
A US-based biopharma with a product addressing a high unmet medical need sought to maximise speed-to-market by filing for registration in multiple countries simultaneously through an international parallel submission programme. The company required strategic guidance on feasibility, programme selection, and regulatory execution across jurisdictions.
03
04
Contribution
Enabled simultaneous multi country registration and accelerated international market entry through assessment of Access Consortium and Project Orbis pathways, jurisdiction selection and submission sequencing.
04
04
Business consequence
Accelerating market access across jurisdictions - directly influencing revenue timeline, partnering attractiveness, and commercial positioning
03
03
How we supported the client
We assisted the client by providing guidance on the filing requirements and process in Switzerland and other countries, identifying potential critical steps and developing a comprehensive filing plan with a clear timetable and key deliverables. We provided ongoing management of any ad hoc issues that arose. Additionally, we identified and subcontracted an experienced partners to support the project as the MAA holder in Switzerland.
Strategic 
Regulatory
Advice
Interactions with Health Authorities
Submission
Management
Partnering with Industry Experts
Strategically laid out options when and where to go for scientific advice in Europe by weighting national versus central advice based on client`s needs and planned development program

Wrote the scientific advice package
/ orphan designation as well as reviewed


Advised on opportunities of acceleration options in Europe

Submitted a request for a SME
(micro, small and medium-sized enterprises)


Client quote
Advyzom TM and therainnova AG formed a Regulatory Transatlantic Collaboration to provide Regulatory strategic advice and comprehensive regulatory services. Our long-term collaboration delivers seamless solutions during development, accelerates market approval, and sets the standard for excellence in EU and US consultancy by adapting ourselves to the highly innovative biotechnology clients we support.
Cynthia Dinella, R. Ph., Pharm.D.
Chief Executive
Officer/President/Founder
© therainnova AG 2026
Follow
Terms and Conditions
Privacy Policy
Design by: G Design Studio
Code: codr.run

© therainnova AG 2026